SPL 334

Drug Profile

SPL 334

Alternative Names: GSNORi - SAJE Pharma; SPL-334

Latest Information Update: 03 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Johns Hopkins University
  • Developer SAJE Pharma
  • Class Small molecules
  • Mechanism of Action Glutathione-independent formaldehyde dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Asthma; Idiopathic pulmonary fibrosis; Inflammation; Parkinson's disease

Highest Development Phases

  • Preclinical Asthma; Idiopathic pulmonary fibrosis; Inflammation; Parkinson's disease

Most Recent Events

  • 02 Mar 2016 SPL 334 is available for licensing as of 02 Mar 2016. http://sajepharma.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top